Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

[1]  M. Kuczyk,et al.  Chemotherapy in Locally Advanced and Metastatic Bladder Cancer , 2004 .

[2]  M. Aristides,et al.  Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer , 2004, Expert review of pharmacoeconomics & outcomes research.

[3]  D. Bajorin.  The phase III candidate: can we improve the science of selection? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. von der Maase.  Gemcitabine in transitional cell carcinoma of the urothelium , 2003, Expert review of anticancer therapy.

[5]  L. Seymour,et al.  Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. , 2002, Urologic oncology.

[6]  H. von der Maase,et al.  Metastatic Urothelial Cancer: Evaluation of Prognostic Factors and Change in Prognosis during the Last Twenty Years , 2001, European Urology.

[7]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Crinò,et al.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Tannock,et al.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.

[14]  W. Catalona.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse: Editorial comment , 1990 .

[15]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[16]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.